Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is that 96 weeks of Rosuvastatin will be safe and effective in
decreasing cardiovascular risk and bone loss in the HIV+ population.